A Randomized, Double-Masked, Active-Controlled, Crossover Phase III Equivalence Study of Generic Dorzolamide 2% versus Innovator Trusopt® Eye Drop Solution in Subjects with Open-Angle Glaucoma or Ocular Hypertension

<table class="table-group" id="tab5"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td class="align_left">Country</td><td class="align_center">Trade name</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td class="align_left">Hungary, Latvia, Poland, Slovakia</td><td class="align_center">Latalux</td></tr><tr><td class="align_left">Germany, Austria, Denmark, Finland, Norway, Sweden</td><td class="align_center">Dorzolamide Tiefenbacher</td></tr><tr><td class="align_left">France</td><td class="align_center">Dorzolamide Alfred E. Tiefenbacher</td></tr><tr><td class="align_left">Germany, Denmark, Norway, Sweden</td><td class="align_center">Dorat 20 mg/ml</td></tr><tr><td class="align_left">Germany, France</td><td class="align_center">Zolasopt 20 mg/ml</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Countries where generic dorzolamide was registered and their trade names.</div>

Journal of Ophthalmology

tab5

Table 5

Table 5: A Randomized, Double-Masked, Active-Controlled, Crossover Phase III Equivalence Study of Generic Dorzolamide 2% versus Innovator Trusopt® Eye Drop Solution in Subjects with Open-Angle Glaucoma or Ocular Hypertension 

Table 5 | A Randomized, Double-Masked, Active-Controlled, Crossover Phase III Equivalence Study of Generic Dorzolamide 2% versus Innovator Trusopt® Eye Drop Solution in Subjects with Open-Angle Glaucoma or Ocular Hypertension 